Literature DB >> 9806543

Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice.

L A Pennacchio1, D M Bouley, K M Higgins, M P Scott, J L Noebels, R M Myers.   

Abstract

Loss-of-function mutations in the gene (CSTB) encoding human cystatin B, a widely expressed cysteine protease inhibitor, are responsible for a severe neurological disorder known as Unverricht-Lundborg disease (EPM1). The primary cellular events and mechanisms underlying the disease are unknown. We found that mice lacking cystatin B develop myoclonic seizures and ataxia, similar to symptoms seen in the human disease. The principal cytopathology appears to be a loss of cerebellar granule cells, which frequently display condensed nuclei, fragmented DNA and other cellular changes characteristic of apoptosis. This mouse model of EPM1 provides evidence that cystatin B, a non-caspase cysteine protease inhibitor, has a role in preventing cerebellar apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806543     DOI: 10.1038/3059

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  62 in total

Review 1.  Genetics of childhood epilepsy.

Authors:  R Robinson; M Gardiner
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

Review 2.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

3.  Differences in aggregation properties of three site-specific mutants of recombinant human stefin B.

Authors:  Manca Kenig; Selma Berbić; Aida Krijestorac; Louise Kroon-Zitko; Magda Tusek; Marusa Pompe-Novak; Eva Zerovnik
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

Review 4.  Cerebellar granule cells as a model to study mechanisms of neuronal apoptosis or survival in vivo and in vitro.

Authors:  Antonio Contestabile
Journal:  Cerebellum       Date:  2002 Jan-Mar       Impact factor: 3.847

Review 5.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

6.  Role of cystatin C in neuroprotection and its therapeutic implications.

Authors:  Luciano D'Adamio
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

7.  Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

Authors:  Dun-Sheng Yang; Philip Stavrides; Panaiyur S Mohan; Susmita Kaushik; Asok Kumar; Masuo Ohno; Stephen D Schmidt; Daniel Wesson; Urmi Bandyopadhyay; Ying Jiang; Monika Pawlik; Corrinne M Peterhoff; Austin J Yang; Donald A Wilson; Peter St George-Hyslop; David Westaway; Paul M Mathews; Efrat Levy; Ana M Cuervo; Ralph A Nixon
Journal:  Brain       Date:  2011-01       Impact factor: 13.501

8.  In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1.

Authors:  Sabina Rabzelj; Vito Turk; Eva Zerovnik
Journal:  Protein Sci       Date:  2005-09-09       Impact factor: 6.725

9.  Transcriptomic analysis in the leech Theromyzon tessulatum: involvement of cystatin B in innate immunity.

Authors:  Christophe Lefebvre; Claude Cocquerelle; Franck Vandenbulcke; David Hot; Ludovic Huot; Yves Lemoine; Michel Salzet
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

Review 10.  Biomarkers of Epileptogenesis: The Focus on Glia and Cognitive Dysfunctions.

Authors:  Annamaria Vezzani; Rosaria Pascente; Teresa Ravizza
Journal:  Neurochem Res       Date:  2017-04-22       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.